{
    "title": "111_hr6331",
    "content": "The Act titled \"Generating Antibiotic Incentives Now Act of 2010\" includes provisions for extending exclusivity period for new qualified infectious disease products. The Act \"Generating Antibiotic Incentives Now Act of 2010\" allows for a 5-year extension of exclusivity period for qualified infectious disease products before approval or licensure. This extension does not apply to supplements or subsequent applications by the same sponsor or manufacturer. The Act allows for a 5-year exclusivity extension for qualified infectious disease products for certain changes or modifications, with a determination by the Secretary within 30 days of request. The Secretary must determine if a drug is a qualified infectious disease product within 30 days of request. Regulations for this section must be promulgated within 12 months of enactment. The exclusivity period for such products prohibits the Secretary from making effective changes for a certain period. The term 'qualified infectious disease product' refers to an antibiotic drug or diagnostic test for treating, detecting, preventing, or identifying resistant gram positive pathogens such as MRSA, VRSA, and VRE. The term 'qualified infectious disease product' includes antibiotics for resistant gram positive pathogens like MRSA, VRSA, and VRE, as well as multi-drug resistant gram negative bacteria, tuberculosis, and other infectious pathogens identified as significant threats to public health due to drug resistance. Section 505E of the Federal Food, Drug, and Cosmetic Act applies to newly approved drugs or biological products. The enactment of this Act affects section 505 of the Federal Food, Drug, and Cosmetic Act and section 351 of the Public Health Service Act. SEC. 4. PRIORITY REVIEW. Amends Chapter V of the Federal Food, Drug, and Cosmetic Act to include a new section for priority review of qualified infectious disease products. SEC. 4 amends the Federal Food, Drug, and Cosmetic Act to prioritize review of qualified infectious disease products. This includes giving priority review to applications for approval or licensure of such products within 6 months. SEC. 5 introduces the concept of a fast track product for drugs intended to treat serious or life-threatening conditions or qualified infectious diseases. SEC. 6 addresses clinical trials. The Secretary must review and revise FDA guidelines for clinical trials of antibiotic drugs within specified timeframes to incorporate advancements in scientific and medical knowledge and ensure clarity on approval procedures. The Secretary is required to review and revise FDA guidelines for antibiotic drug clinical trials, addressing animal models, in vitro techniques, surrogate markers, trial types, and delta values. Reports to Congress on progress are mandated annually for 4 years. The section does not impact FDA guidelines unless revised by the Secretary. The Food and Drug Administration provides recommendations for investigations on drugs intended to treat, detect, prevent, or identify qualifying pathogens before approval or licensing. If the Secretary believes a drug is a qualified infectious disease product, written recommendations for nonclinical and clinical investigations may be requested by the sponsor. The Secretary provides written recommendations for nonclinical and clinical investigations for drugs that are considered qualified infectious disease products, necessary for approval or licensing under specific acts. The term \"biological product\" is defined in this section. The term \"drug\" is defined in section 201 of the Federal Food, Drug, and Cosmetic Act. The term \"qualifying pathogen\" is defined in section 505E of the Federal Food, Drug, and Cosmetic Act. The term \"Secretary\" refers to the Secretary of Health and Human Services."
}